Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiam Chemaitelly

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
American Journal of Epidemiology|December 7, 2023
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study designHoussein H Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
Nature Medicine|November 3, 2021
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in QatarPatrick Tang, Mohammad R Hasan, Hiam Chemaitelly, et al.
The Lancet. Infectious Diseases|March 13, 2023
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort studyHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
The Lancet. Microbe|November 14, 2022
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort studyHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
Eclinicalmedicine|August 3, 2023
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational studySuelen H Qassim, Hiam Chemaitelly, Houssein H Ayoub, et al.
Vaccine|April 15, 2024
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradientLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Plos One|January 31, 2022
Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2Peter V Coyle, Reham Awni El Kahlout, Soha R Dargham, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 17, 2023
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort studyHiam Chemaitelly, Jeremy Samuel Faust, Harlan M Krumholz, et al.
Iscience|May 31, 2021
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individualsPeter V Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
Emerging Infectious Diseases|April 26, 2021
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, QatarAndrew Jeremijenko, Hiam Chemaitelly, Houssein H Ayoub, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
American Journal of Epidemiology|December 7, 2023
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study designHoussein H Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
Nature Medicine|November 3, 2021
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in QatarPatrick Tang, Mohammad R Hasan, Hiam Chemaitelly, et al.
The Lancet. Infectious Diseases|March 13, 2023
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort studyHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
The Lancet. Microbe|November 14, 2022
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort studyHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
Eclinicalmedicine|August 3, 2023
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational studySuelen H Qassim, Hiam Chemaitelly, Houssein H Ayoub, et al.
Vaccine|April 15, 2024
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradientLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Plos One|January 31, 2022
Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2Peter V Coyle, Reham Awni El Kahlout, Soha R Dargham, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 17, 2023
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort studyHiam Chemaitelly, Jeremy Samuel Faust, Harlan M Krumholz, et al.
Iscience|May 31, 2021
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individualsPeter V Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
Emerging Infectious Diseases|April 26, 2021
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, QatarAndrew Jeremijenko, Hiam Chemaitelly, Houssein H Ayoub, et al.
Pageof 16